Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients
NCT06901297Phase 3Recruiting
- Sponsor
- Materia Medica Holding
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 3 trial of raphamin in acute rhinosinusitis (ARS), sponsored by Materia Medica Holding. Started Apr 2025; status: recruiting.
02
Drugs
raphamin
03
Conditions
acute rhinosinusitis (ARS)
Beyond the preview
Go deeper on NCT06901297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06901297.